Genfit Sa · EURONEXT:GNFT
Genfit Sa — Investor Presentation (April 2026)
32 slides from Genfit Sa's investor presentation, April 2026
Slide 1: Corporate Presentation
Corporate Presentation April 2026
Slide 2: Disclaimer
Disclaimer IMPORTANT NOTICE – YOU MUST READ THE FOLLOWING BEFORE CONTINUING. THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANCE IS BASED UPON OR DERIVED FROM INFORMATION PROVIDED B
Slide 3: Strategic Highlights and Value Drivers
Strategic Highlights and Value Drivers NEXT STEPS Ipsen’s Iqirvo® in PBC: Strong commercial sales1 trajectory 1 Major contributor to GENFIT’s financial strength (>US$200M first full year) Ipsen 1Q26 results (April 23, 2026) 2 MASH Diagnostics: Upcoming momentum from therapeutics Therapeutics market
Slide 4: 1. Who we are
1. Who we are 2. Iqirvo® in PBC & PSC 3. MASH Diagnostics 4. Our lead clinical-stage assets in ACLF & CCA 5. Other research programs in ACLF & UCD/OA
Slide 5: Corporate Highlights
Corporate Highlights French biopharmaceutical company Listed on EURONEXT “GNFT” 4 growth drivers in addition to PBC 25+ years in liver diseases, taking + MASH Non-invasive diagnostic technology early assets to commercial stage1 + CCA Phase 2 (GNS561 combination) Catalysts + ACLF Phase 2 (G1090N/NTZ)
Slide 6: Pipeline
Pipeline Preclinical Phase 1 Phase 2 Phase 3 Next expected/targeted steps2 ► CLINICAL Programs1 ACLF G1090N/NTZA,3 Phase 1 completed Potential initiation of Phase 2 POCC targeted 2H26 Continuum* CCA GNS561A Phase 1b on going (dose escalation) Potential initiation of Phase 2 targeted 2H26 ► RESEARCH
Slide 7: Targeting Untapped Markets with High Potential
Targeting Untapped Markets with High Potential ACLF 294,000 in 2021, US, EU4, UK | ~300,000 by 2036 ~$4Bn for grade 1-2 ACLF in US, EU4, UK by 2030 CCA 20,000 to 30,000 for US, EU4, UK ~$3.1Bn for US, EU4, UK UCD/OA 2,000 to 3,000 for US, EU4, UK ~$1.1Bn for US, EU4, UK PBC ~385,000 for Global ~$1.5
Slide 8: 2. Iqirvo in PBC & PSC
1. Who we are 2. Iqirvo® in PBC & PSC 3. MASH Diagnostics 4. Our lead clinical-stage assets in ACLF & CCA 5. Other research programs in ACLF & UCD/OA
Slide 9: Solid Commercial Performance from Ipsen
Solid Commercial Performance from Ipsen Iqirvo® sales (global, quarterly) since commercial launch1 €283,4M First full year net sales €78,8M €184M €204,6M Cumulative milestone payments received2 €76,6M €105.5M €128,0M €48,6M €79,4M €35,5M Cumulative royalties €43,9M received3 $23,3M €20,6M €14,3M €24
Slide 10: PSC: Ongoing Phase 3 Launched by Ipsen
PSC: Ongoing Phase 3 Launched by Ipsen Click here for details on this trial (Ipsen’s 2025 Full‑Year Results) Click here for details on this trial (Ipsen’s 2025 Full-Year Results) In February 2026, Ipsen confirmed the initiation of the first and only global Phase 3 clinical trial, addressing a signif
Slide 11: 3. MASH Diagnostics
1. Who we are 2. Iqirvo® in PBC & PSC 3. MASH Diagnostics 4. Our lead clinical-stage assets in ACLF & CCA 5. Other research programs in ACLF & UCD/OA
Slide 12: MASH: Non-invasive diagnostic technology
MASH: Non-invasive diagnostic technology 2025 Highlights 2026 Outlook 12 PR: GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Slide 13: 4. Our lead clinical-stage assets in ACLF & CCA
Acute-on-Chronic Liver Failure (ACLF) Life-threatening worsening of pre-existing advanced chronic liver disease covering a broad spectrum of conditions across a disease continuum including acute decompensation (AD) of liver cirrhosis and hepatic encephalopathy (HE) G1090N/NTZ │ SRT-015 │ CLM-022 │ V
Slide 14: ACLF: A High Unmet Medical Need
ACLF: A High Unmet Medical Need CHRONIC PHASE ACUTE PHASE Acute Chronic Liver Disease Cirrhosis ACLF 23-74% mortality at 28 days Decompensation = UNDERLYING CONDITION = PRECIPITANT ≥ 1 ORGAN DYSFUNCTIONS/FAILURES ► NO APPROVED DRUGS Bacterial Alcohol Alcohol Viruses Kidney Cerebral Infection Consump
Slide 15: Our approach in ACLF Continuum: Targeting Multiple Pathways
Our approach in ACLF Continuum: Targeting Multiple Pathways Acute Insult LIVER CIRRHOSIS/CLD • Immune-mediated tissue damage 1 • Mitochondrial dysfunction Liver Dysfunction 1 • Oxidative Stress • Dysbiosis Gut/Liver axis Portal • Bacterial Hypertension 1-2-3 5 translocation 4 • Cell Death • PAMPs Hy
Slide 16: ACLF Continuum: R&D Programs
ACLF Continuum: R&D Programs We are developing a diversified pipeline based on pathophysiology Research Collaboration to better address the complexities of the condition and improve treatment outcomes with EVerZom1 G1090N/NTZ SRT-015 CLM-022 VS-02-HE EViv Oral Injectable Oral Injectable Anti-inflamm
Slide 17: Our Lead Asset in ACLF: G1090N/NTZ
Our Lead Asset in ACLF: G1090N/NTZ A Strong Scientific Rationale Findings to date: G1090N/NTZ ✓ Decreases systemic inflammation in animal models, including in ACLF models ✓ Protects liver, kidney & brain in rat models of ACLF by decreasing tissue damage Anti-inflammatory Oral ✓ Protects mice from mo
Slide 18: G1090N/NTZ: Phase 1 Study Design
G1090N/NTZ: Phase 1 Study Design CT.gov #: NCT07110441 A Phase 1 open-label study to assess pharmacokinetics, safety, and tolerability G1090N/NTZ of G1090N in healthy subjects Anti-inflammatory Oral Key inclusion criteria Investigational drug G1090N is • Healthy Volunteers a promising therapy in ACL
Slide 19: G1090N/NTZ's Potential Recently Confirmed in the Clinic
G1090N/NTZ’s Potential Recently Confirmed in the Clinic G1090N/NTZ Anti-inflammatory Oral The safety profile observed in Phase 1 and the consistent biological activity evidenced in ex vivo assays represent a meaningful step in development. These findings position G1090N as a promising candidate for
Slide 20: 4. Our lead clinical-stage assets in ACLF & CCA
Acute-On-Chronic Liver Failure (ACLF) G1090N/NTZ │ SRT-015 │ CLM-022 │ VS-02-HE │ EViv Cholangiocarcinoma (CCA) Malignancy of bile ducts. Without treatment <20% of patients survive 5 years from diagnosis1. KRAS mutation is not addressed by current treatments. GNS561 1. Who we are 2. Iqirvo® in PBC &
Slide 21: CCA with KRAS Mutation: A High Unmet Medical Need
CCA with KRAS Mutation: A High Unmet Medical Need Rare and aggressive liver malignancy ~30% of patients with CCA harbor KRAS mutations4 that develops in the bile ducts • one of the most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways5 • As th
Slide 22: Rationale for Combining Anticancer Therapies and GNS561
Rationale for Combining Anticancer Therapies and investigational drug GNS561, an Autophagy Inhibitor GNS561 PPT1 inhibitor in #1 Anticancer Therapies combination with a MEK inhibitor Oral #2 GNS561 Chemotherapeutic agents (Autophagy inhibitor) MAP Kinase pathway targeted therapies By entering the ly
Slide 23: GNS561: Phase 1b/2a Study Design
GNS561: Phase 1b/2a Study Design CT.gov #: NCT05874414 GNS561 A Phase 1b/2a open-label, multicenter study to evaluate safety, pharmacokinetics (PK), pharmacodynamics PPT1 inhibitor in (PD) and efficacy of GNS561 in combination with trametinib in advanced KRAS mutated CCA after failure of combination
Slide 24: Phase 1b: Highly Encouraging Early Data
Phase 1b: Highly Encouraging Early Data GNS561 PPT1 inhibitor in combination with a MEK inhibitor Oral Advanced KRAS-mutated cholangiocarcinoma remains a formidable clinical challenge, and the emerging activity seen in this initial study is encouraging. Because MEK inhibition alone has historically
Slide 25: Moving Forward
Moving Forward • Phase 1b dose escalation will continue as planned to confirm activity signal • 1H26 - Completion expected results will be used to establish recommended Phase 2 combination doses • 2H26 – targeted Phase 2 initiation Beyond CCA: a potential to explore the benefit of autophagy inhibiti
Slide 26: 5. Other research programs in ACLF & UCD/OA
Acute-on-Chronic Liver Failure (ACLF) Life-threatening worsening of pre-existing advanced chronic liver disease covering a broad spectrum of conditions across a disease continuum including acute decompensation (AD) of liver cirrhosis and hepatic encephalopathy (HE) G1090N/NTZ │ SRT-015 │ CLM-022 │ V
Slide 27: SRT-015
SRT-015 Findings to date: SRT-015 ✓ Decreases systemic inflammation in animal models, including in an ACLF model ASK1 ✓ Protects mice from mortality in a model of sepsis induced by gut leakage inhibitor Injectable ✓ Demonstrates efficacy when injected in mice with acute liver failure (AASLD24 poster
Slide 28: CLM-022
CLM-022 Findings to date: CLM-022 ✓ Protects the liver in pre-clinical ALF models NLRP3 ✓ Protects mice from mortality induced by gut leakage-induced sepsis inflammasome ✓ Dose-dependently inhibits IL-1β secretion (AASLD 2024 poster) inhibitor ✓ Shows potent inhibition of priming and activation step
Slide 29: VS-02-HE
VS-02-HE About ▪ One of the most common complications of liver cirrhosis and ACLF Hepatic ▪ A central nervous system disorder representing a diverse spectrum of neurologic symptoms VS-02-HE ▪ Excess ammonia induces alteration of cell metabolism and can result in brain edema Encephalopathy Urease inh
Slide 30: EViv: A Research Collaboration with EVerZom
Eviv: A Research Collaboration with EVerZom EViv Exosome Technology Injectable 30 Press release
Slide 31: 5. Other research programs in ACLF & UCD/OA
Acute-On-Chronic Liver Failure (ACLF) G1090N/NTZ │ SRT-015 │ CLM-022 │ VS-02-HE │ EViv Urea Cycle Disorders (UCD) & Organic Acidemias (OA) Ultra-rare disease: 1,900 HAC2,3,4 per year in children in US+EU4+UK. High mortality (75% at 5 years2). Survivors often have severe brain injuries. Neonatal RRT
Slide 32: VS-01-HAC in UCD/OA
VS-01-HAC in UCD/OA Findings to date: VS-01-HAC ✓ Preclinical proof of concept: Potential bridging • VS-01 achieved robust ammonia clearance, ranging from 6.0 ± 2.8 mL/min on Day 1 to 9.5 ± 3.8 mL/min on Day 101,2,3,4 therapy or first-line in minipigs treatment Peritoneal ✓ Clinical proof of concept